|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MCM5 |
Gene summary for MCM5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MCM5 | Gene ID | 4174 |
| Gene name | minichromosome maintenance complex component 5 | |
| Gene Alias | CDC46 | |
| Cytomap | 22q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000724 | UniProtAcc | B1AHB0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4174 | MCM5 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.49e-03 | 3.02e-01 | -0.1207 |
| 4174 | MCM5 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.33e-02 | 2.14e-01 | -0.1526 |
| 4174 | MCM5 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.69e-05 | 2.63e-01 | -0.1464 |
| 4174 | MCM5 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.18e-07 | 2.98e-01 | -0.059 |
| 4174 | MCM5 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.63e-04 | 3.30e-01 | -0.0842 |
| 4174 | MCM5 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.56e-05 | 2.49e-01 | 0.096 |
| 4174 | MCM5 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.46e-07 | 2.38e-01 | 0.0674 |
| 4174 | MCM5 | LZE2T | Human | Esophagus | ESCC | 1.51e-07 | 5.37e-01 | 0.082 |
| 4174 | MCM5 | LZE4T | Human | Esophagus | ESCC | 2.73e-09 | 2.74e-01 | 0.0811 |
| 4174 | MCM5 | LZE7T | Human | Esophagus | ESCC | 4.02e-16 | 9.11e-01 | 0.0667 |
| 4174 | MCM5 | LZE8T | Human | Esophagus | ESCC | 1.14e-05 | 3.51e-01 | 0.067 |
| 4174 | MCM5 | LZE22T | Human | Esophagus | ESCC | 9.94e-07 | 6.49e-01 | 0.068 |
| 4174 | MCM5 | LZE24T | Human | Esophagus | ESCC | 1.73e-11 | 3.36e-01 | 0.0596 |
| 4174 | MCM5 | LZE21T | Human | Esophagus | ESCC | 2.19e-08 | 5.78e-01 | 0.0655 |
| 4174 | MCM5 | LZE6T | Human | Esophagus | ESCC | 9.65e-12 | 5.04e-01 | 0.0845 |
| 4174 | MCM5 | P1T-E | Human | Esophagus | ESCC | 6.81e-05 | 5.89e-01 | 0.0875 |
| 4174 | MCM5 | P2T-E | Human | Esophagus | ESCC | 4.31e-42 | 1.01e+00 | 0.1177 |
| 4174 | MCM5 | P4T-E | Human | Esophagus | ESCC | 3.68e-15 | 4.18e-01 | 0.1323 |
| 4174 | MCM5 | P5T-E | Human | Esophagus | ESCC | 6.33e-16 | 3.34e-01 | 0.1327 |
| 4174 | MCM5 | P8T-E | Human | Esophagus | ESCC | 7.61e-19 | 5.25e-01 | 0.0889 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0032392 | Colorectum | AD | DNA geometric change | 31/3918 | 90/18723 | 2.02e-03 | 1.63e-02 | 31 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:00062612 | Esophagus | ESCC | DNA-dependent DNA replication | 100/8552 | 151/18723 | 2.61e-07 | 3.94e-06 | 100 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:003239214 | Esophagus | ESCC | DNA geometric change | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:003250813 | Esophagus | ESCC | DNA duplex unwinding | 58/8552 | 84/18723 | 1.23e-05 | 1.14e-04 | 58 |
| GO:00062701 | Esophagus | ESCC | DNA replication initiation | 27/8552 | 34/18723 | 6.01e-05 | 4.62e-04 | 27 |
| GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
| GO:00007241 | Esophagus | ESCC | double-strand break repair via homologous recombination | 79/8552 | 138/18723 | 4.05e-03 | 1.62e-02 | 79 |
| GO:00007251 | Esophagus | ESCC | recombinational repair | 80/8552 | 140/18723 | 4.10e-03 | 1.63e-02 | 80 |
| GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
| GO:003239211 | Liver | HCC | DNA geometric change | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
| GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
| GO:00325081 | Liver | HCC | DNA duplex unwinding | 49/7958 | 84/18723 | 2.46e-03 | 1.19e-02 | 49 |
| GO:0006261 | Liver | HCC | DNA-dependent DNA replication | 80/7958 | 151/18723 | 5.91e-03 | 2.44e-02 | 80 |
| GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
| GO:00323925 | Oral cavity | OSCC | DNA geometric change | 59/7305 | 90/18723 | 3.03e-07 | 4.63e-06 | 59 |
| GO:00325083 | Oral cavity | OSCC | DNA duplex unwinding | 55/7305 | 84/18723 | 8.05e-07 | 1.12e-05 | 55 |
| GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
| GO:00062611 | Oral cavity | OSCC | DNA-dependent DNA replication | 84/7305 | 151/18723 | 2.46e-05 | 2.30e-04 | 84 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa030304 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0303011 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
| hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa03030 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa030301 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
| hsa030302 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
| hsa0411022 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
| hsa030303 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
| hsa0411032 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MCM5 | SNV | Missense_Mutation | novel | c.1421N>C | p.Ile474Thr | p.I474T | P33992 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MCM5 | insertion | Frame_Shift_Ins | novel | c.1174_1175insGGGGCAC | p.Lys392ArgfsTer56 | p.K392Rfs*56 | P33992 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| MCM5 | insertion | Nonsense_Mutation | novel | c.1176_1177insACATGAAGAAGGCCATTGCCTGCC | p.Lys392_Phe393insThrTerArgArgProLeuProAla | p.K392_F393insT*RRPLPA | P33992 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| MCM5 | SNV | Missense_Mutation | rs149623832 | c.1627N>A | p.Ala543Thr | p.A543T | P33992 | protein_coding | tolerated(0.08) | possibly_damaging(0.869) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MCM5 | SNV | Missense_Mutation | novel | c.1777G>A | p.Ala593Thr | p.A593T | P33992 | protein_coding | tolerated(0.12) | benign(0.031) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MCM5 | SNV | Missense_Mutation | c.598G>A | p.Asp200Asn | p.D200N | P33992 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-EA-A6QX-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MCM5 | SNV | Missense_Mutation | c.2170N>T | p.Arg724Cys | p.R724C | P33992 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-Q1-A6DV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MCM5 | SNV | Missense_Mutation | c.1069C>T | p.Leu357Phe | p.L357F | P33992 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| MCM5 | SNV | Missense_Mutation | c.475N>G | p.Ser159Ala | p.S159A | P33992 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MCM5 | SNV | Missense_Mutation | c.518N>A | p.Arg173His | p.R173H | P33992 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |